Statute
BPCIA
102 published works
BioLoquitur
Webinar: Biosimilar Litigation and Your BPCIA Compliance: Key Strategies In Light of AbbVie v. Boehringer
By Dean L. Fanelli, Ph.D., Jamaica Szeliga
This webinar is hosted by The Knowledge Group. On March 22nd at 12 p.m. ET, Dean Fanelli and Jamaica Szeliga, along with Timothy Shea of Sterne, Kessler, Goldstein & Fox…
IP Intelligence
Federal Circuit Suggests Solution to Patent Owner’s Dilemma When Applicant for Biosimilar Product Refuses Discovery
By Allen Sokal
In Amgen, Inc. v. Hospira, Inc., Appeal No. 2016-2179 (Fed. Cir. Aug. 10, 2017), the Federal Circuit suggested what an owner of a reference product suing an applicant for a…
The IP Law Blog
U.S. Supreme Court Allows Early Notice For Biosimilars
In SANDOZ INC. v. AMGEN INC. et al., the United States Supreme Court in a unanimous opinion ruled that biosimilar makers can give their required 180-day statutory notice of sales…
Biosimilars Law Blog
Supreme Court Issues Landmark Biosimilar Ruling
By Philip Katz, David Fox, Gary Veron, James Allred
On June 12, 2017, the Supreme Court issued a unanimous ruling in Sandoz Inc. v. Amgen Inc. The case interprets two provisions of the Biologics Price Competition and Innovation Act…
Biosimilars Law Bulletin
Janssen Files BPCIA Patent Infringement Suit Against Samsung Bioepis’s Renflexis® (infliximab-abda)
Earlier this month, Janssen Biotech, Inc., a subsidiary of Johnson and Johnson, (“Janssen” or “Plaintiff”) filed a Complaint in the United States District Court for the District of New Jersey…
Biosimilars Law Bulletin
Litigation Spotlight: The Infliximab (Remicade®) Litigation
Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and only two of those products are commercially…
Biosimilars Law Bulletin
Briefing Completed in Supreme Court’s First Biosimilar Case
As we previously reported in this post, the Supreme Court granted certiorari in its first biosimilar case on Sandoz’s petition in Sandoz, Inc. v. Amgen, Inc., et al., Case No.…
IP Intelligence
A Split Decision Remains Split; No en banc Review of Amgen v. Sandoz
By Ron Kern
On October 16, 2015, the Court of Appeals for the Federal Circuit (“Federal Circuit”) opted not to rehear its previously issued split decision in the court’s first analysis of the…
Biosimilars Law Blog
FDA Updates U.S. Biosimilar Guidances
Five years after enactment of the BPCIA and following its first biosimilar approval, the U.S. Food and Drug Administration finalized its initial guidances describing the scientific and regulatory expectations for…
PTABWatch
Hatch-Waxman and BPCIA Patents May Be Exempted from Post-Grant Proceedings Under Pending Senate Legislation
On Thursday, June 4, the Senate Judiciary Committee approved the Protecting American Talent and Entrepreneurship (PATENT) Act. We previously reported the significant provisions of the bill. Several members of the…